Guidance on the use of liquid-based cytology for cervical screening

  • Technology appraisal guidance
  • TA69
  • Published: 
Download guidance (PDF)

9 Sources of evidence considered by the Committee

The following documentation and opinions were made available to the Committee:

The assessment report for this appraisal, which was prepared by the School of Health and Related Research (ScHARR), University of Sheffield.

  • Karnon J, Peters J, Chilcott J et al. Liquid-based cytology in cervical screening: an updated rapid and systematic review, January 2003

The following document (English Pilot Study report) was used to inform the assessment report:

  • Moss SM, Gray A, Legood R et al. Evaluation of HPV/LBC: cervical screening pilot studies. First report to the DOH on evaluation of LBC (revised January 2003).

The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope, assessment report and the appraisal consultation document. Consultee organisations were provided with the opportunity to appeal against the FAD:

Manufacturer/sponsors:

  • Cytyc UK Limited

  • Surgipath Europe Limited

  • Tripath Imaging Europe/PathLore Limited

Trade organisations:

  • Association of British Health-Care Industries

  • British In Vitro Diagnostics Association

Professional/specialist and patient/carer groups:

  • British Society for Clinical Cytology

  • British Society of Colposcopy and Cervical Pathology

  • Cancer Research UK

  • Department of Health

  • Institute of Biomedical Science

  • Macmillan Cancer Relief

  • Marie Curie Cancer Care

  • Medical Women's Federation

  • National Association of Cytologists

  • National Cancer Alliance

  • Pathological Society of Great Britain and Ireland

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal Society of Obstetricians and Gynaecologists

  • Royal College of Pathologists

  • South West Wales Cancer Network

  • Welsh Assembly Government

Commentator organisations (without the right of appeal):

  • Institute of Cancer Research

  • National Cancer Research Institute

  • National Collaborating Centre for Women and Children's Health

  • Newcastle upon Tyne Hospitals NHS Trust

  • NHS Cancer Screening Programmes

  • NHS Confederation

  • NHS Purchasing and Supplies Agency

  • NHS Quality Improvement Scotland

  • Norfolk and Norwich University Hospital NHS Trust

  • North Bristol NHS Trust

The following individuals were selected from clinical expert and patient advocate nominations from the professional/specialist and patient/carer groups. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on liquid-based cytology by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD:

  • Mrs Maggie Cooper, Cervical Screening Developments Coordinator, Marie Curie Cancer Care

  • Mr Nick Dudding, Cytology Department, Royal Hallamshire Hospital

  • Ms Eileen Hewer, Assistant Director of QA, Northern General Hospital, Sheffield (Institute of Biomedical Science)

  • Dr Amanda Herbert, Chair, British Society for Clinical Cytology

  • Professor Henry Kitchener, Professor of Gynaecological Oncology, St Mary's Hospital, Manchester

  • Dr Ray Lonsdale, Consultant Histopathologist and Clinical Director, Norfolk and Norwich University Hospital

  • Dr Phillip Wilson, Consultant Pathologist, St George's Hospital, Tooting

ISBN: 978-1-4731-6125-415